Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

367 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Neointimal myofibroblasts contribute to maintaining Th1/Tc1 and Th17/Tc17 inflammation in giant cell arteritis.
Greigert H, Ramon A, Genet C, Cladière C, Gerard C, Cuidad M, Corbera-Bellalta M, Alba-Rovira R, Arnould L, Creuzot-Garcher C, Martin L, Tarris G, Ghesquière T, Ouandji S, Audia S, Cid MC, Bonnotte B, Samson M. Greigert H, et al. Among authors: creuzot garcher c. J Autoimmun. 2024 Jan;142:103151. doi: 10.1016/j.jaut.2023.103151. Epub 2023 Dec 1. J Autoimmun. 2024. PMID: 38039746 Free article.
Human monocyte-derived suppressive cells (HuMoSC) for cell therapy in giant cell arteritis.
Samson M, Genet C, Corbera-Bellalta M, Greigert H, Espígol-Frigolé G, Gérard C, Cladière C, Alba-Rovira R, Ciudad M, Gabrielle PH, Creuzot-Garcher C, Tarris G, Martin L, Saas P, Audia S, Bonnotte B, Cid MC. Samson M, et al. Front Immunol. 2023 Feb 21;14:1137794. doi: 10.3389/fimmu.2023.1137794. eCollection 2023. Front Immunol. 2023. PMID: 36895571 Free PMC article.
Correction: Full-field optical coherence tomography for the diagnosis of giant cell arteritis.
Maldiney T, Greigert H, Martin L, Benoit E, Creuzot-Garcher C, Gabrielle PH, Chassot JM, Boccara C, Balvay D, Tavitian B, Clément O, Audia S, Bonnotte B, Samson M. Maldiney T, et al. Among authors: creuzot garcher c. PLoS One. 2023 Dec 19;18(12):e0296315. doi: 10.1371/journal.pone.0296315. eCollection 2023. PLoS One. 2023. PMID: 38113232 Free PMC article.
[Brimonidine-induced interstitial keratitis: Case report].
Szwarcberg L, Gabrielle PH, Guillarme-Sallit R, Creuzot-Garcher C, Arnould L. Szwarcberg L, et al. Among authors: creuzot garcher c. J Fr Ophtalmol. 2024 Mar 12;47(6):104122. doi: 10.1016/j.jfo.2024.104122. Online ahead of print. J Fr Ophtalmol. 2024. PMID: 38479333 French. No abstract available.
Predicting the retinal content in omega-3 fatty acids for age-related macular-degeneration.
Acar N, Merle BMJ, Ajana S, He Z, Grégoire S, Hejblum BP, Martine L, Buaud B, Bron AM, Creuzot-Garcher CP, Korobelnik JF, Berdeaux O, Jacqmin-Gadda H, Bretillon L, Delcourt C; Biomarkers of Lipid Status And metabolism in Retinal ageing (BLISAR) Study Group. Acar N, et al. Clin Transl Med. 2021 Jul;11(7):e404. doi: 10.1002/ctm2.404. Clin Transl Med. 2021. PMID: 34323423 Free PMC article. No abstract available.
Photocoagulation or sham laser in addition to conventional anti-VEGF therapy in macular edema associated with TelCaps due to diabetic macular edema or retinal vein occlusion (TalaDME): a study protocol for a multicentric, French, two-group, non-commercial, active-control, observer-masked, non-inferiority, randomized controlled clinical trial.
Dupas B, Castro-Farias D, Girmens JF, Eginay A, Couturier A, Villeroy F, Delyfer MN, Creuzot-Garcher C, Giocanti-Auregan A, Béral L, Arndt C, Mesnard C, Vicaut E, Chaumet-Riffaud P, Durand-Zaleski I, Paques M. Dupas B, et al. Among authors: creuzot garcher c. Trials. 2024 Apr 22;25(1):273. doi: 10.1186/s13063-024-07994-1. Trials. 2024. PMID: 38649937 Free PMC article.
Three-year outcomes of vascular endothelial growth factor inhibitors in naïve branch retinal vein occlusion: Fight Retinal Blindness!
Alforja S, Hunt A, Nguyen V, O'Toole L, Gabrielle PH, Invernizzi A, Mehta H, Ponsioen TL, Squirrell D, Casaroli-Marano RP, Barthelmes D, Gillies MC, Zarranz-Ventura J; Fight Retinal Blindness (FRB) users group. Alforja S, et al. Ophthalmol Retina. 2024 Apr 17:S2468-6530(24)00189-1. doi: 10.1016/j.oret.2024.04.014. Online ahead of print. Ophthalmol Retina. 2024. PMID: 38641007
One-Year Anti-VEGF Therapy Outcomes in Diabetic Macular Edema Based on Treatment Intensity: Data from the Fight Retinal Blindness! Registry.
Mehta H, Gabrielle PH, Hashimoto Y, Kibret GD, Arnold J, Guillaumie T, Kheir WJ, Kok G, Vujosevic S, O'Toole L, Mangelschots E, Jaross N, Ceklic L, Daien V, Viola F, Squirrell D, Lavid FJ, Creuzot-Garcher C, Barthelmes D, Gillies M; Fight Retinal Blindness! Study Group. Mehta H, et al. Among authors: creuzot garcher c. Ophthalmol Retina. 2024 Apr 16:S2468-6530(24)00182-9. doi: 10.1016/j.oret.2024.04.008. Online ahead of print. Ophthalmol Retina. 2024. PMID: 38615818 Free article.
No association of endothelial lipase and aldose reductase polymorphisms with proliferative diabetic retinopathy: Results of the French prospective multicenter REDIAGEN study.
Henry A, Boigelot T, Moura TF, Leclercq I, Barbe C, Thiery A, Djerada Z, Nazeyrollas P, Clavel C, Cornillet-Lefebvre P, Berrod JP, Creuzot-Garcher C, Meyer L, Gaucher D, Guerci B, Lenoble P, Milazzo S, Perone JM, Arndt C, Durlach V. Henry A, et al. Among authors: creuzot garcher c. Diabetes Metab. 2024 May;50(3):101533. doi: 10.1016/j.diabet.2024.101533. Epub 2024 Apr 1. Diabetes Metab. 2024. PMID: 38570135 No abstract available.
367 results